- In February 2024, Pfizer Inc. announced the expansion of its live attenuated vaccines production facility in the U.S., aimed at increasing output capacity for vaccines targeting measles and rubella. This strategic move is in response to rising global demand and is expected to enhance Pfizer’s distribution capabilities in developing nations, reinforcing its leadership in the live vaccines segment
- In January 2024, Serum Institute of India Pvt. Ltd. launched an affordable, high-efficacy live attenuated rotavirus vaccine tailored for low- and middle-income countries. The initiative aligns with the company's mission to promote equitable access to immunization and strengthens its presence in the global pediatric vaccine market
- In November 2023, Sanofi entered a public-private partnership with the European Commission to develop next-generation live attenuated vaccines for emerging viral diseases. This collaboration emphasizes innovation and preparedness amid rising concerns over global epidemics, positioning Sanofi as a major innovator in the market.
- In September 2023, Merck & Co., Inc. received expanded FDA approval for its live attenuated MMR (measles, mumps, rubella) vaccine to be used in adults aged 50 and above. The approval opens new demographic segments for the product, supporting market growth in the preventive vaccine domain
- In August 2023, GlaxoSmithKline plc (GSK) launched a new live attenuated varicella vaccine in Latin America, addressing unmet needs in childhood immunization programs. This regional expansion is part of GSK’s broader initiative to increase global immunization coverage through public health collaborations
- In July 2023, MedImmune, LLC, the biologics division of AstraZeneca, initiated Phase III clinical trials for its next-gen live attenuated intranasal influenza vaccine. The new formulation aims to offer broader protection against flu strains with improved mucosal immunity, signaling a major step forward in intranasal vaccine delivery technologies.
- In May 2023, Emergent BioSolutions, Inc. signed a contract with the U.S. Department of Health and Human Services to develop and stockpile live attenuated vaccines for biodefense applications, particularly targeting smallpox and other Category A threatsThis move enhances national preparedness and secures the company’s role in government-led health initiatives
- In March 2023, CSL Limited completed the acquisition of a biotechnology startup specializing in live attenuated vaccine platforms using mRNA-assisted attenuation techniques. The acquisition is aimed at bolstering CSL’s R&D capabilities and diversifying its live vaccine pipeline to address emerging infectious diseases
